BiomX Inc: Rises on therapy to target bacteria in colorectal cancer patients

Biomx

10/12/2020 10:20

** Drug developer's shares  PHGE.K  rise 11% to $6.64
premarket
    ** Co says successfully engineered a gene payload to target
a type of bacteria present in tumors of patients with colorectal
cancer
    ** Analysis confirmed presence of a target bacteria called
Fusobacterium nucleatum in over 80% of such tumor samples - PHGE
 urn:newsml:reuters.com:*:nBw4hpk8ca
    ** PHGE's colorectal cancer program uses phage therapy or
bacteria-attacking virus with checkpoint inhibitors to target
such bacteria    
    ** Up to Wednesday's close, stock down 38.3% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))